Free EORTC Bladder Cancer Calculator

EORTC Bladder Cancer Calculator: Assessing Recurrence and Progression Risk in NMIBC

The EORTC bladder cancer recurrence and progression calculator is a free online tool designed to estimate the probability of tumor recurrence and disease progression in patients with non-muscle invasive bladder cancer (NMIBC) over one- and five-year horizons. By incorporating six key clinical and pathological parameters, this NMIBC risk assessment tool assists healthcare professionals in tailoring treatment decisions and follow-up schedules based on validated EORTC risk tables for bladder cancer.

Background on Bladder Cancer

Bladder cancer is the most common malignancy of the urinary tract, predominantly affecting individuals over 60 years of age, with a higher incidence in males. Smoking remains the single most important risk factor (also linked to lung and kidney cancers). The hallmark symptom is painless hematuria (blood in the urine); when present, bladder cancer (or kidney cancer) should always be ruled out.

Approximately 75% of newly diagnosed cases are non-muscle invasive (stage Ta, T1, or CIS), while the remaining 25% already exhibit muscle-invasive or advanced disease. Patients with NMIBC generally have a favorable survival outlook, but the condition carries a substantial risk of intravesical recurrence, and in some cases progression to more advanced stages.

Parameters Used in the EORTC Scoring System

The calculator’s predictions are derived from the scoring system originally published by Sylvester et al., based on data from nearly 2,600 patients. Each of six variables is assigned points for both recurrence and progression, as shown in the table below.

Table 1: EORTC Risk Points for Recurrence and Progression

Factor	Recurrence Points	Progression Points
Number of tumors
Single	0	0
2–7	3	3
≥8	6	3
Tumor diameter
<3 cm	0	0
≥3 cm	3	3
Prior recurrence rate
Primary	0	0
≤1 rec/year	2	2
>1 rec/year	4	2
Stage (T category)
Ta	0	0
T1	1	4
Concomitant CIS
No	0	0
Yes	1	6
Grade (WHO 1973)
G1	0	0
G2	1	0
G3	2	5
Total score range	0–17	0–23

Note: Carcinoma in situ (CIS) is always high-risk and requires immediate treatment; its presence significantly worsens the prognosis.

Conversion of Total Scores to Risk Percentages

Once the recurrence and progression points are tallied, they are translated into estimated probabilities using the EORTC risk tables:

Table 2: Recurrence Risk by Total Score

Total Score	1‑Year Risk (%)	5‑Year Risk (%)
0	15	31
1–4	24	46
5–9	38	62
10–17	61	78

Table 3: Progression Risk by Total Score

Total Score	1‑Year Risk (%)	5‑Year Risk (%)
0	0.2	0.8
2–6	1	6
7–13	5	17
14–23	17	45

Thus, the one-year recurrence probability ranges from 15% to 61%, and the progression probability from below 1% to 17%. At five years, recurrence spans 31% to 78% and progression from less than 1% to 45%.

Clinical Utility

By applying a patient’s specific data to these tables, the urologist can objectively stratify risk and discuss appropriate management options—such as intravesical therapy, cystectomy, or surveillance frequency—in line with the European Association of Urology (EAU) guidelines for NMIBC. This calculator serves as a practical implementation of the validated EORTC risk tables for bladder cancer, enabling a data-driven approach to the non-muscle invasive bladder cancer prognosis.

Remember that this tool is not a substitute for clinical expertise; it should be used as a supplementary resource in shared decision‑making with the patient.